Biodesign Staple Line Reinforcement

K170945 · Cook Biotech Incorporated · OXE · Apr 28, 2017 · General, Plastic Surgery

Device Facts

Record IDK170945
Device NameBiodesign Staple Line Reinforcement
ApplicantCook Biotech Incorporated
Product CodeOXE · General, Plastic Surgery
Decision DateApr 28, 2017
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 878.3300
Device ClassClass 2
AttributesTherapeutic

Intended Use

The SURGIS SLR Staple Line Reinforcement is intended for use as a prosthesis for the surgical repair of soft tissue deficiencies using surgical staplers. The device may be used for buttressing and reinforcing staple lines during lung resection (e.g. wedge resection, blebectomy, bullectomy, bronchial resection, segmentectomy, pneumonectomy/pneumectomy, pneumoreduction) and other incisions of the lung and bronchus. The device can be used for the reinforcement of the gastric staple line during bariatric surgical procedures of gastric bypass and gastric banding, and for reinforcement of staple lines during small bowel, mesentery, colon and colorectal procedures. The device may be used with anastomotic staplers or with non-anastomotic staplers.

Device Story

Biodesign Staple Line Reinforcement is a porcine-derived small intestinal submucosa (SIS) implant; acellular collagen-rich extracellular matrix. Device acts as a mechanical buttress for surgical staple lines; prevents staple tearing through soft tissue; remodels into body over time. Used in OR by surgeons during lung, gastric, and bowel procedures. Provided on foam applicator in foil pouch; single-use. No electronic components or software.

Clinical Evidence

Bench testing only. Includes staple line leakage testing to verify mechanical performance and buttressing capability. Biocompatibility leveraged from predicate device per ISO 10993-1:2009.

Technological Characteristics

Material: Porcine small intestinal submucosa (SIS). Form: Multi-layer strip (2-layer or 4-layer) on polystyrene foam applicator. Dimensions: 76-176 mm length, 10-12 mm width, 50-500 μm thickness. Sterilization: E-beam. No energy source or connectivity.

Indications for Use

Indicated for patients requiring soft tissue repair via surgical staplers, including lung, gastric (bariatric), small bowel, mesentery, colon, and colorectal procedures.

Regulatory Classification

Identification

Surgical mesh is a metallic or polymeric screen intended to be implanted to reinforce soft tissue or bone where weakness exists. Examples of surgical mesh are metallic and polymeric mesh for hernia repair, and acetabular and cement restrictor mesh used during orthopedic surgery.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other. Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 April 28, 2017 Cook Biotech Incorporated Mr. Perry Guinn Vice President, Regulatory Affairs 1425 Innovation Place West Lafayette, Indiana 47906 Re: K170945 Trade/Device Name: Biodesign Staple Line Reinforcement Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical Mesh Regulatory Class: Class II Product Code: OXE, FTM Dated: March 28, 2017 Received: March 30, 2017 Dear Mr. Guinn: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device {1}------------------------------------------------ related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely, # David Krause -S for Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ #### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration ## Indications for Use 510(k) Number (if known) Device Name Biodesign Staple Line Reinforcement #### Indications for Use (Describe) The SURGIS SLR Staple Line Reinforcement is intended for use as a prosthesis for the surgical repair of soft tissue deficiencies using surgical staplers. The device may be used for buttressing and reinforcing staple lines during lung resection (e.g. wedge resection, blebectomy, bullectomy, bronchial resection, segmentectomy, pneumonectomy/pneumectomy, pneumoreduction) and other incisions of the lung and bronchus. The device can be used for the reinforcement of the gastric staple line during bariatric surgical procedures of gastric bypass and gastric banding, and for reinforcement of staple lines during small bowel, mesentery, colon and colorectal procedures. The device may be used with anastomotic staplers or with non-anastomotic staplers. | Type of Use (Select one or both, as applicable) | |-------------------------------------------------| |-------------------------------------------------| X Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ # 510(k) Summary #### I. SUBMITTER Cook Biotech Incorporated 1425 Innovation Place West Lafayette, IN 47906 Phone: (765) 497-3355 Contact Person: Perry W. Guinn Date Prepared: 28 March 2017 #### DEVICE II. | Name of Device: | Biodesign® Staple Line Reinforcement | |-----------------------|--------------------------------------| | Common or Usual Name: | Surgical Mesh | | Classification Name: | Surgical Mesh | | Product Code: | FTM (21 CFR §878.3300) | | Regulatory Class: | Class II | #### III. PREDICATE DEVICE SURGISIS® SLRTM Staple Line Reinforcement (K070405, Cook Biotech Incorporated) ### IV. DEVICE DESCRIPTION The Biodesign® Staple Line Reinforcement device is part of a family of implant devices manufactured from porcine small intestine that are disinfected and processed to remove the tunica mucosa from the inner intestinal surface and tunica muscularis from the outer intestinal surface. The resulting membrane is a three dimensional, acellular, collagen-rich extracellular matrix (ECM) that is termed small intestinal submucosa (SIS). Biodesign® Staple Line Reinforcement consists of a thin multi-layer strip of SIS, pre-coated with an adhesive that eliminates the need for a separate adhesive (e.g. hydrogel) to affix the device to surgical stapler jaws. The single-use device is provided on a foam applicator and suspended in a form-fitting tray before being sealed in a foil pouch and sterilized (E-beam). The material composition, general manufacturing processes, packaging configuration and sterilization method of the subject device are identical to the predicate, SURGISIS® SLRTM Staple Line Reinforcement (K070405). {4}------------------------------------------------ Upon implantation, the Biodesign® Staple Line Reinforcement device will provide mechanical reinforcement of the staple line by buttressing the soft tissue and preventing the surgical staples from tearing through the affected tissue. In addition, the Biodesign® Staple Line Reinforcement device will incorporate (remodel) into the body over time such that no graft material is left behind. #### INDICATIONS FOR USE v. The Biodesign® Staple Line Reinforcement is intended for use as a prosthesis for the surgical repair of soft tissue deficiencies using surgical staplers. The device may be used for buttressing and reinforcing staple lines during lung resection (e.g. wedge resection, blebectomy, lobectomy, bullectomy, bronchial resection, segmentectomy, pneumonectomy/pneumectomy, pneumoreduction) and other incisions and excisions of the lung and bronchus. The device can be used for the reinforcement of the gastric staple line during bariatric surgical procedures of gastric bypass and gastric banding, and for reinforcement of staple lines during small bowel, mesentery, colon and colorectal procedures. The device may be used with anastomotic staplers or with non-anastomotic staplers. # VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE The Biodesign® Staple Line Reinforcement device is identical to its predicate in that they are both intended for use as a prosthesis for the surgical repair of soft tissue deficiencies using surgical staplers. Moreover, the subject device's component materials, general manufacturing processes, fundamental scientific technology, and mode of action remain unchanged from the predicate. The only modification to the Biodesign® Staple Line Reinforcement devices is the addition of thinner configurations (dimensional change) to the already existing line of staple line reinforcement devices. Table 5-1 provides a comparison of the subject and predicate devices. {5}------------------------------------------------ | | Biodesign® Staple Line Reinforcement<br>(subject device) | SURGISIS® SLRTM Staple Line<br>Reinforcement<br>(predicate device) | |----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Device | | | | Manufacturer | Cook Biotech, Inc. | Cook Biotech, Inc. | | 510 (k) Number | Not assigned | K070405 | | Product Code | FTM | FTM | | Intended Use | Intended for use as a prosthesis for the<br>surgical repair of soft tissue deficiencies<br>using surgical staplers. The device may<br>be used for buttressing and reinforcing<br>staple lines during lung resection (e.g.<br>wedge resection, blebectomy,<br>lobectomy, bullectomy, bronchial<br>resection, segmentectomy,<br>pneumonectomy/pneumectomy,<br>pneumoreduction) and other incisions<br>and excisions of the lung and bronchus.<br>The device can be used for the<br>reinforcement of the gastric staple line<br>during bariatric surgical procedures of<br>gastric bypass and gastric banding, and<br>for reinforcement of staple lines during<br>small bowel, mesentery, colon and<br>colorectal procedures. The device may<br>be used with anastomotic staplers or<br>with non-anastomotic staplers. | Intended for use as a prosthesis for the<br>surgical repair of soft tissue deficiencies<br>using surgical staplers. The device may<br>be used for buttressing and reinforcing<br>staple lines during lung resection (e.g.<br>wedge resection, blebectomy,<br>lobectomy, bullectomy, bronchial<br>resection, segmentectomy,<br>pneumonectomy/pneumectomy,<br>pneumoreduction) and other incisions<br>and excisions of the lung and bronchus.<br>The device can be used for the<br>reinforcement of the gastric staple line<br>during bariatric surgical procedures of<br>gastric bypass and gastric banding, and<br>for reinforcement of staple lines during<br>small bowel, mesentery, colon and<br>colorectal procedures. The device may<br>be used with anastomotic staplers or<br>with non-anastomotic staplers. | | Materials and<br>Components | SIS buttressing strip<br>Pre-coated adhesive<br>Polystyrene foam applicator | SIS buttressing strip<br>Pre-coated adhesive<br>Polystyrene foam applicator | | SIS Device<br>Dimensions<br>(unfolded) | Length: 76 mm to 176 mm<br>Width: 10 mm to 12 mm<br>Thickness: 4-layer SIS<br>(100 μm to 500 μm)<br>2-layer SIS<br>(50 μm to 300 μm) | Length: 76 mm to 176 mm<br>Width: 10 mm to 12 mm<br>Thickness: 4-layer SIS<br>(100 μm to 500 μm) | | Shelf-Life | 18 months | 18 months | | Packaging | foil pouch | foil pouch | | Sterilization | E-beam | E-beam | | One-time Use | Yes | Yes | ### Table 5-1. Substantial Equivalence Information {6}------------------------------------------------ ### VII. PERFORMANCE DATA The following performance data were provided in support of the substantial equivalence determination. #### Biocompatibility testing Biocompatibility of the predicate device has been established in accordance with ISO 10993-1:2009 – Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process to demonstrate that the device is safe for permanent contact (>30 days) implantation. The predicate test data was leveraged to support the substantial equivalence of the subject device as the device materials and general manufacturing processes are identical for the subject and predicate devices. #### Non-Clinical testing Product verification testing was performed on sterilized finished devices to evaluate the mechanical performance of the subject device for its intended use. Staple line leakage testing confirms that the Biodesign® Staple Line Reinforcement provides adequate staple line buttressing for use as a prosthesis for the surgical repair of soft tissue deficiencies using surgical staplers. #### VIII. CONCLUSIONS For purposes of determinations of substantial equivalence under section 513(i) of the FD&C Act (21 U.S.C. § 360c(i)), the Biodesign® Staple Line Reinforcement device has the same intended use and functions under the same mode of action and fundamental scientific technology as the predicate device. In addition, the subject device is composed of the same materials and manufactured using the same processes as the predicate. The only design modification is with regard to device dimensions, where the subject device includes thinner configurations to supplement the existing line of SIS staple line reinforcement devices. The absence of changes in the fundamental scientific technology and intended use of the device, as well as a risk analysis and completion of verification and validation activities, provide evidence to support the conclusion that the thickness modification does not introduce new risks and that the subject device performs comparably to the predicate device that is currently marketed for the same intended use.
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%